TY - JOUR
T1 - Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer
AU - Sugiura, Yasoo
AU - Fujimoto, Hiroyuki
AU - Yamamoto, Munehiro
AU - Nomura, Hisashi
AU - Hashizume, Toshinori
AU - Kawai, Osamu
AU - Araki, Norito
AU - Kawakami, Kotaro
AU - Sueki, Hitoshi
AU - Fusegawa, Hisae
AU - Ohkubo, Yasuyuki
AU - Nemoto, Etsuo
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-related adverse events. Case presentation: A 66-year-old man without any history of autoimmune disease was referred to our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage IDA non-small-cell lung cancer by using bronchoscopic biopsy, computed tomography, and FDG-PET. After a single course of cisplatin and pemetrexed, the tumor size increased remarkably and the regimen was changed to nivolumab (3mg/kg every 2 weeks). Psoriasis and psoriatic arthritis were observed after 4 courses of nivolumab. Nivolumab treatment continued, and the oral administration of prednisolone (20 mg/day) could improve psoriasis and psoriatic arthritis. However, the lung cancer showed progressive disease after the 11th course of nivolumab. Conclusion: Psoriasis and psoriatic arthritis were induced by nivolumab in the patient without any history of autoimmune disease. It is unclear how prednisolone affected nivolumab for the treatment of lung cancer.
AB - Background: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-related adverse events. Case presentation: A 66-year-old man without any history of autoimmune disease was referred to our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage IDA non-small-cell lung cancer by using bronchoscopic biopsy, computed tomography, and FDG-PET. After a single course of cisplatin and pemetrexed, the tumor size increased remarkably and the regimen was changed to nivolumab (3mg/kg every 2 weeks). Psoriasis and psoriatic arthritis were observed after 4 courses of nivolumab. Nivolumab treatment continued, and the oral administration of prednisolone (20 mg/day) could improve psoriasis and psoriatic arthritis. However, the lung cancer showed progressive disease after the 11th course of nivolumab. Conclusion: Psoriasis and psoriatic arthritis were induced by nivolumab in the patient without any history of autoimmune disease. It is unclear how prednisolone affected nivolumab for the treatment of lung cancer.
KW - Lung cancer
KW - Nivolumab
KW - Prednisolone
KW - Psoriasis and psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85037640146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037640146&partnerID=8YFLogxK
M3 - Article
C2 - 28912410
AN - SCOPUS:85037640146
SN - 0385-0684
VL - 44
SP - 787
EP - 789
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 9
ER -
